ARD-101 Update Call - AARDVARK THERAPEUTICS INC

Financial Performance:

• No traditional revenue, earnings, or cash flow metrics reported as ARD-101 is an investigational drug in clinical development.
• The transcript indicates the termination of the HERO and Open-Label Extension (OLE) trials, with 67 patients enrolled in HERO prior to the February pause.
• No specific debt or deferred revenue figures were disclosed; the focus is on R&D spend related to the halted trials and the subsequent TQT study.
• The company is currently in a pre-revenue phase, having spent capital on clinical trials, healthy volunteer studies, and regulatory interactions to resolve the clinical hold.

Guidance and Future Outlook:

• The FDA clinical hold on the ARD-101 Investigational New Drug (IND) was officially lifted last week.
• The company plans to request a meeting with the FDA to align on the design of a Phase 3 trial intended to support a future marketing application.
• Future dosing will be capped below 800 mg twice daily based on TQT study results showing no QRS or QT prolongation at lower doses (200 mg and 400 mg).
• Management aims to demonstrate efficacy and safety in a new Phase 3 design, potentially utilizing a randomized withdrawal study, pending FDA alignment.
• Recruitment for future trials is expected to be feasible despite the presence of the approved competitor Viocit, driven by high community engagement and unmet need.

Business Segments and Product Lines:

• Product: ARD-101, an oral bitter taste receptor agonist (TAS2Rs) designed to activate gut receptors to release satiety hormones (CCK and GLP-1), signaling via the vagus nerve to dampen hunger.
• Indication: Hyperphagia in Prader-Willi syndrome (PWS).
• Clinical Data: HERO trial data is exploratory due to early termination; however, it showed early and consistent efficacy signals where patients improved on ARD-101 and lost improvement upon discontinuation.
• Open-Label Extension: 19 patients entered the OLE; those switching from placebo to ARD-101 showed an additional 6-point improvement in HQCT scores.
• Safety: Drug was generally well-tolerated; the single serious cardiac event was attributed to a drug-drug interaction with pitolisant at the 800 mg dose.

Market and Competitive Landscape:

• Unmet Need: Hyperphagia is the most challenging aspect of PWS, affecting patients' quality of life and safety (risk of stomach rupture); current management relies on environmental controls rather than pharmacotherapy.
• Competitor: Viocit-XR (relinoxamine) is the only approved treatment but does not work for all patients and is contraindicated for some due to comorbidities; it primarily "takes the edge off" rather than fully resolving hyperphagia.
• Competition: Other companies are developing therapies with different mechanisms, but the PWS community remains highly engaged and willing to participate in trials.
• Market Position: Management believes ARD-101's mechanism (gut-brain axis via vagus nerve) avoids the nausea associated with systemic GLP-1 therapies and offers a distinct value proposition.

Risks and Challenges:

• Cardiac Safety: The program was paused and placed on hold due to QRS widening in healthy volunteers at doses above 400 mg and a serious cardiac event in HERO linked to a drug-drug interaction with pitolisant (CYP2D6 inhibition).
• Regulatory Uncertainty: The Phase 3 trial design is not yet finalized; success depends on FDA alignment regarding the new protocol and whether HERO data can contribute to the registrational package.
• Trial Limitations: The truncated duration of HERO and OLE limits statistical power and the ability to assess long-term metabolic effects or sustained efficacy.
• Drug-Drug Interactions: ARD-101 at 800 mg is a strong CYP2D6 inhibitor; the interaction profile at the proposed lower therapeutic doses remains to be fully characterized.
• Placebo Response: Significant placebo response observed in PWS trials, which may complicate the interpretation of efficacy signals.

Management Commentary and Tone:

• Tone was cautiously optimistic and confident in the continued development of ARD-101 despite the clinical trial interruptions.
• Management emphasized that the efficacy signal is "directional" and consistent with Phase 2 data, noting the rapid onset and offset of effects align with a drug mechanism.
• The team expressed strong gratitude to patients, families, and advocacy groups for their continued engagement despite the pause.
• Dr. Lee (CEO) and Dr. Jamin (CMO) focused heavily on the resolution of the safety issue and the path forward, asserting that the lower dose strategy mitigates cardiac risks.

Analyst Questions and Answers:

• Data Interpretation: Analysts questioned the discrepancy between Week 12 and OLE Week 0 data; management clarified this is due to the requirement to re-administer HQCT9 assessments at the transition, causing minor baseline shifts.
• Dosing Strategy: Management confirmed no clear dose-response relationship was observed between 200 mg and 800 mg, with 200 mg showing comparable efficacy in some metrics, supporting the move to lower doses.
• Safety Monitoring: Future trials will include rigorous cardiac monitoring; the 800 mg QRS widening was deemed reversible and asymptomatic in healthy volunteers, and no such signal was seen at 200/400 mg.
• Competitor Interaction: Management expects to exclude patients on Viocit-XR in the new Phase 3 trial to isolate the drug signal, though ARD-101 may eventually be used in combination or for non-responders.
• Recruitment: Dr. Bird (investigator) and management expressed confidence in recruitment rates, citing the high engagement of the PWS community and the persistent unmet need.
• Future Mechanism: No specific updates were given on R201 (the next program), with focus remaining entirely on PWS.

Other Key Points:

• Mechanism Distinction: ARD-101 acts peripherally (gut) to avoid central nausea often seen with GLP-1s, a key differentiator highlighted by management.
• Community Engagement: The PWS advocacy groups and families were described as "highly sophisticated" and "super engaged," with no struggle observed in enrollment history.
• Publication Plans: The company is currently working on a publication strategy for the HERO and OLE data but has not committed to a specific timeline.
• Safety Event Specifics: The serious cardiac event in HERO was re-evaluated as a drug-drug interaction with pitolisant (a known CYP2D6 substrate) rather than a direct effect of ARD-101 on the heart at the administered dose in that patient.